Literature DB >> 23506964

Distal ureterectomy is a safe surgical option in patients with urothelial carcinoma of the distal ureter.

Orietta Dalpiaz1, Georg Ehrlich2, Franz Quehenberger3, Karl Pummer2, Richard Zigeuner2.   

Abstract

OBJECTIVES: We evaluated cancer-specific survival (CSS) and recurrence-free survival (RFS) rates of open distal ureterectomy (DU) compared with radical nephroureterectomy (RNU) for urothelial carcinoma of the distal ureter. METHODS AND MATERIALS: We retrospectively considered patients with urothelial carcinoma of the distal ureter who underwent DU or RNU at our department. Survival analysis and Cox regression models compared CSS and RNU after DU and RNU. RFS was evaluated separately for bladder and upper tract. Covariates were age, gender, symptoms at diagnosis, pathologic stage and grade, associated carcinoma in situ, surgical margins, lympho-vascular invasion, multifocality, necrosis, and previous or concomitant bladder cancer.
RESULTS: Forty-nine and 42 patients underwent DU and RNU, respectively. Median patients' follow-up was 51.5 months (range 4-290 mo). Two patients (4%) in the DU group were diagnosed with a recurrence in the ipsilateral upper tract after 63 and 45 months, respectively. Both patients underwent nephroureterectomy and are still alive in strict follow-up for non-muscle invasive bladder recurrence. Contralateral upper tract recurrence was observed in 1 and 3 patients in the RNU and DU group, respectively. At 5 years, CSS and RFS (upper tract) rates were 77% and 91% for DU and 78% and 96% for RNU, respectively. On univariable and multivariable analyses the type of surgery did not influence CSS and RFS (P = 0.92 and P = 0.94).
CONCLUSIONS: DU is a safe surgical option in patients with urothelial carcinoma of the distal ureter and does not compromise oncologic outcomes compared with RNU.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Recurrence; Survival; Upper urinary tract; Ureter; Ureterectomy; Urothelial carcinoma

Mesh:

Year:  2013        PMID: 23506964     DOI: 10.1016/j.urolonc.2013.01.001

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  8 in total

1.  Segmental ureterectomy is not inferior to radical nephroureterectomy for either middle or distal ureter urothelial cell carcinomas within 3.5 cm.

Authors:  Chen Fang; Xin Xie; Tianyuan Xu; Wei He; Hongchao He; Xiaojing Wang; Yu Zhu; Zhoujun Shen; Yuan Shao
Journal:  Int Urol Nephrol       Date:  2017-03-25       Impact factor: 2.370

Review 2.  Risk-adapted strategy for the kidney-sparing management of upper tract tumours.

Authors:  Thomas Seisen; Pierre Colin; Morgan Rouprêt
Journal:  Nat Rev Urol       Date:  2015-02-24       Impact factor: 14.432

Review 3.  A systematic review and meta-analysis of oncological and renal function outcomes obtained after segmental ureterectomy versus radical nephroureterectomy for upper tract urothelial carcinoma.

Authors:  D Fang; T Seisen; K Yang; P Liu; X Fan; N Singla; G Xiong; L Zhang; X Li; L Zhou
Journal:  Eur J Surg Oncol       Date:  2016-08-25       Impact factor: 4.424

Review 4.  Nephron-sparing surgery for the management of upper tract urothelial carcinoma: an outline of surgical technique and review of outcomes.

Authors:  Ruchira Nandurkar; Marnique Basto; Shomik Sengupta
Journal:  Transl Androl Urol       Date:  2020-12

5.  Segmental ureteroileal conduit resection for the treatment of distal upper urinary tract recurrence of bladder cancer following cystectomy.

Authors:  Shu-Xiong Zeng; Xin Lu; Wei-Dong Xu; Zhen-Sheng Zhang; Hai-Hang Li; Ying-Hao Sun; Chuan-Liang Xu
Journal:  Chin J Cancer       Date:  2016-01-21

6.  Oncologic outcomes comparison of partial ureterectomy and radical nephroureterectomy for urothelial carcinoma.

Authors:  Shengxian Li; Yuchen Pan; Jinghai Hu
Journal:  BMC Urol       Date:  2019-11-21       Impact factor: 2.264

7.  Preoperative sterile pyuria as a prognostic biomarker for intravesical recurrence in upper urinary tract urothelial carcinoma.

Authors:  Byeong Jo Jeon; Bum Sik Tae; Hoon Choi; Jae Hyun Bae; Jong Wook Kim; Hong Seok Park; Jae Young Park
Journal:  Investig Clin Urol       Date:  2019-12-19

Review 8.  Nephron-sparing approaches in the management of upper tract urothelial carcinoma: indications and clinical outcomes.

Authors:  Young Hwii Ko
Journal:  Transl Cancer Res       Date:  2020-10       Impact factor: 1.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.